TRIGELAN 200 mg/50 mg/200 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

trigelan 200 mg/50 mg/200 mg

g.l. pharma gmbh - austria - combinatii (levodopum+carbidopum+entacaponum) - compr. film. - 200mg/50mg/200mg - agenti dopaminergici dopa si derivati

LEVODOPA/CARBIDOPA/ENTACAPONA MYLAN 50 mg/12,5 mg/200 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levodopa/carbidopa/entacapona mylan 50 mg/12,5 mg/200 mg

generics (uk) ltd - combinatii (levodopum+carbidopum+entacaponum) - compr. film. - 50mg/12,5mg/200mg - agenti dopaminergici dopa si derivati

LEVODOPA/CARBIDOPA/ENTACAPONA MYLAN 75 mg/18,75 mg/200 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levodopa/carbidopa/entacapona mylan 75 mg/18,75 mg/200 mg

generics (uk) ltd - combinatii (levodopum+carbidopum+entacaponum) - compr. film. - 75mg/18,75mg/200mg - agenti dopaminergici dopa si derivati

LEVODOPA/CARBIDOPA/ENTACAPONA MYLAN 100 mg/25 mg/200 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levodopa/carbidopa/entacapona mylan 100 mg/25 mg/200 mg

generics (uk) ltd - combinatii (levodopum+carbidopum+entacaponum) - compr. film. - 100mg/25mg/200mg - agenti dopaminergici dopa si derivati

LEVODOPA/CARBIDOPA/ENTACAPONA MYLAN 125 mg/31,25 mg/200 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levodopa/carbidopa/entacapona mylan 125 mg/31,25 mg/200 mg

generics (uk) ltd - combinatii (levodopum+carbidopum+entacaponum) - compr. film. - 125mg/31,25mg/200mg - agenti dopaminergici dopa si derivati

LEVODOPA/CARBIDOPA/ENTACAPONA MYLAN 150 mg/37,5 mg/200 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levodopa/carbidopa/entacapona mylan 150 mg/37,5 mg/200 mg

generics (uk) ltd - combinatii (levodopum+carbidopum+entacaponum) - compr. film. - 150mg/37,5mg/200mg - agenti dopaminergici dopa si derivati

LEVODOPA/CARBIDOPA/ENTACAPONA MYLAN 200 mg/50 mg/200 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levodopa/carbidopa/entacapona mylan 200 mg/50 mg/200 mg

generics (uk) ltd - combinatii (levodopum+carbidopum+entacaponum) - compr. film. - 200mg/50mg/200mg - agenti dopaminergici dopa si derivati

LECIGON 20 mg/5 mg/20 mg/ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lecigon 20 mg/5 mg/20 mg/ml

bioglan ab - suedia - combinatii (levodopum+carbidopum+entacaponum) - gel intestinal - 20mg/5mg/20mg/ml - agenti dopaminergici dopa si derivati

Kymriah Uniunea Europeană - română - EMA (European Medicines Agency)

kymriah

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - alți agenți antineoplazici - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Tecartus Uniunea Europeană - română - EMA (European Medicines Agency)

tecartus

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantle-cell - agenți antineoplazici - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).